dopamine News
-
Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients. The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, ...
By Renishaw plc
-
S1 Biopharma Announces Expanded Analysis Of Phase 2A Data On Lorexys™ For Treatment Of Hypoactive Sexual Desire Disorder Based On Pgic Scale To Be Presented At 2019 Isswsh/Issm Joint Meeting
New York, NY – Jan. 4, 2019 – S1 Biopharma, Inc. (S1) announced today that researchers will present an expanded analysis of data from the company’s Phase 2a clinical trial of Lorexys™ for the treatment of women with hypoactive sexual desire disorder (HSDD) based on the Patient Global Impression of Change (PGIC) scale. Robert E. Pyke, MD, PhD, president of Pykonsult, LLC, ...
-
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson`s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, ...
-
S1 Biopharma And Ckd Pharmaceuticals Announce Commercialization Agreement For Lorexys™ In South Korea For Treatment Of Hypoactive Sexual Desire Disorder (Hsdd) In Women
NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, and CKD Pharmaceuticals, a leading pharmaceutical company in South Korea, today announced that they have entered into a commercialization agreement for Lorexys™, S1 ...
-
EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
EndoLogic announced that the FDA accepted the cardiac safety trial for renzapride in patients with gastroparesis. That study demonstrated no evidence of QTc prolongation in the EKG findings. The U.S. Food and Drug Administration (FDA) views this study as sufficient to characterize renzapride’s QTc prolongation potential at both therapeutic (4 mg per day) and supra-therapeutic (20 mg per ...
-
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson`s Disease
BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD). ...
-
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson’s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate “Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson’s Disease (PD).” This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients ...
-
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. The FDA’s ...
-
XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). Over ...
-
BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and ...
-
BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 ...
-
EndoLogic Acquires Renzapride from Alizyme, plc
EndoLogic, a company focused on the development and commercialization of products that treat gastrointestinal diseases, has acquired the worldwide rights to the clinical-stage asset, renzapride, from Alizyme, plc. Renzapride has been in clinical development for use as a prokinetic agent for the gastrointestinal tract. EndoLogic plans on developing the compound for the treatment of gastroparesis. ...
-
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 `TRAVERS` Clinical Trial of AM-125 for the Treatment of Acute Vertigo
HAMILTON, BERMUDA / ACCESSWIRE / February 14, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in Part B of the Phase 2 ‘TRAVERS' clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The Company expects to release top-line results ...
-
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other ...
By Vaxxinit
-
Lauren Sciences LLC awarded second Michael J. Fox Foundation grant to further develop V-Smart Therapeutic for Parkinson`s disease
New York, N.Y., June 25, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company continuing development of its novel V-Smart™ platform technology, announced today the award of a second grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF). The company recently completed the first stage of developing V-Smart™-based therapeutics for the treatment of ...
-
Women who start prenatal vitamins early are less likely to have children with autism
Women who reported not taking a daily prenatal vitamin immediately before and during the first month of pregnancy were nearly twice as likely to have a child with an autism spectrum disorder as women who did take the supplements — and the associated risk rose to seven times as great when combined with a high-risk genetic make-up, a study by researchers at the UC Davis MIND Institute has ...
-
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has executed a Master Services Agreement (MSA) with Societal CDMO, Inc. (NASD: SCTL), a bi-coastal contract development and manufacturing ...
By Cingulate
-
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the ...
By Cingulate
-
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the completion of its study assessing the effect of food on absorption of its lead candidate CTx-1301, an investigational medication for the ...
By Cingulate
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you